Copyright 2017 MedInvent, LLC | All Rights Reserved
The NasoNeb® Nasal Nebulizer is a registered trademark by MedInvent, LLC.
Pulmicort Respules® is a trademark of AstraZeneca
The NasoNeb System is protected under US PATENT 8,146,587, 8,162,921, 8,925,544, 9,402,947, 9,440,020 & other patents pending.
Home | Nasal Nebulizer | How To Use | Where to Purchase | Resources | In The News | Testimonials
Following intranasal administration of BDP in healthy males, the systemic absorption was assessed by measuring the plasma concentrations of its active metabolite B-17-MP, for which the absolute bioavailability following intranasal administration is 44% (95% CI 28%, 70%). After intranasal administration, <1% of the dose is absorbed by the nasal mucosa. The remainder after being cleared from the nose, either by drainage or mucocilary clearance, is available for absorption from the gastrointestinal tract. Plasma B-17-MP is almost entirely due to conversion of BDP absorbed from the swallowed dose.